Supernus soars on Indivior merger, Q2 revenue beat
SUPN•Deal terms and leadership
Indivior stockholders are to receive a one-time special cash dividend of $1.0 billion in aggregate before the deal closes. Supernus shareholders are to receive 1.5401 shares of Indivior per Supernus share.
The new entity will be named Supernus, and the current CEO of Supernus, Jack Khattar, will lead it.
The deal is expected to close in the fourth quarter of 2026.
Quarterly revenue beats estimates
Supernus posted second-quarter revenue of $219.06 million, beating analysts' estimates of $204.96 million, according to data compiled by LSEG.
As of the last close, the stock was down 10.2% year to date.
Shares rise on merger announcement
Supernus Pharmaceuticals' shares SUPN.O rose 16.5% to $52 premarket.
The company said it will merge with Indivior Pharmaceuticals INDV.O to create a diversified biopharmaceutical company specialized in the central nervous system.
